We specialize in antibody discovery, protein engineering, synthetic biology, and digital biotechnology and work with a multitude of protein scaffolds. These include human monoclonal antibodies, nanobodies, and other binding proteins that we utilize as precision molecules to combat and diagnose diseases, engineer microbiomes, and solve challenges within industrial biotechnology.

We believe that science should be conducted for the benefit of society. To achieve this, our research focuses both on scientific and technological insight, as well as translational aspects and practical applications. Moreover, we actively engage in innovation and entrepreneurship, and have successfully spun out several biotech companies.

On the technology side, the center focuses on developing monoclonal antibodies and nanobodies with special binding properties, oligoclonal antibody and nanobody mixtures and designer antigens. These antibodies and nanobodies can be used for broad neutralization of multiple targets at low doses, or selective targeting of critical key factors involved in disease and pathogenesis. Designer antigens, on the other hand, can be used for novel vaccine applications and for specialized antibody discovery.

Our expertise in these fields allows us to design advanced biotherapeutics, diagnostic tools, and molecules for feed, food, and biocontrol purposes. We see antibodies and antigens as precision engineering tools that can used to design molecules that target specific anatomical sites, that are robust under harsh conditions, or that can be manufactured at ultra-low cost.